Figure 4.
The relative benefit of statins, PCSK9 inhibitors, ezetimibe, and placebo against adverse events and neurocognitive events in patients with hypercholesterolemia. Data are presented with odds ratios and 95% confidence intervals. PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease.